Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup